secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0000950170-24-036006
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health FY 2023 revenue down 36% to $1.2M; net loss narrows to $8.2M
-------------------------------------------------------------------------

- Revenue $1.2M (-36% YoY) on 52% fewer unit sales; ASP up 46%.
- Net loss improved to $8.2M from $10.1M; cash $3.4M, no debt.
- Raised $7.9M via two public offerings in 2023; executed 1-for-100 reverse split and regained Nasdaq compliance.
- Completed enrollment for VNS pilot study in Feb 2024; results pending.
- Named to Fast Company's Most Innovative Companies 2023 in Medical Device.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024036006/0000950170-24-036006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024036006/tivc-20240325.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer